<DOC>
	<DOCNO>NCT00208065</DOCNO>
	<brief_summary>The primary objective study evaluate histamine , CGRP VIP level saliva biological marker activation trigeminal parasympathetic nerve fiber various clinical presentation primary headache compare allergic rhinosinusitis control population .</brief_summary>
	<brief_title>Evaluation Histamine , CGRP VIP Markers Activation Trigeminal Parasympathetic Nerve Fibers</brief_title>
	<detailed_description>It suggest many people self-diagnosed physician diagnose `` sinus '' headache experience symptom fulfill diagnostic criterion migraine migrainous headache . The shared symptomatology differentiate disorder . `` Sinus '' symptom early manifestation migraine may associate elevated level CGRP suggest peripheral trigeminal activation whereas `` sinus '' symptom late migraine may associate elevation VIP suggest parasymptathetic activation . Subjects without autonomic `` sinus '' symptom change salivatory histamine , CGRP VIP value similar control . Subjects rhinosinusitis level pattern salivatory histamine , CGRP VIP unique migraine subject . If `` sinus symptom '' associate parasympathetic activation , detectable increase VIP early course nasal symptom development , conversely , symptom associate trigeminal activation , increase CGRP detect . Five group 10 subject recruit . Group A without migraine , self-described `` sinus '' headache symptom rhinosinusitis . Group B chronic rhinosinusitis history migraine `` sinus '' headache . Group C `` sinus '' headache symptom meet IHS criterion migraine symptom rhinosinusitis precede onset headache symptom meet migraine criterion . Group D symptoms rhinosinusitis develop late course migraine criterion IHS migraine meet . Group E IHS migraine , without sinus symptom associate migraine .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Almotriptan</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<criteria>Group A : history migraine , selfdescribed sinus headache symptom allergic rhinosinusitis Group B : history chronic recurrent rhinosinusitis without infection Group C , D , E : fulfill criterion IHS migraine Group C D : fulfill protocol criterion sinus symptom associate migraine Group E : fulfill criterion IHS migraine history sinus symptom Age 1865 , male female Must good health If female , postmenopausal least 1 yr hysterectomy tubal ligation incapable pregnancy practice protocol list method contraception negative urine pregnancy test Visit 1 Able understand communicate study observer Able take oral medication adhere perform study procedure Able read comprehend write instruction willing complete procedure Willingness participate signing Informed Consent More 15 headache day per month Pathology salivary gland sialadenitis History hypersensitivity pseudoephedrin subject assign Group B triptanlike medication Group A , C , D , E. Subjects diabetes , salivary gland tumor , liver disease , alcoholism , and/or neuropathy Pregnant nursing Subjects condition would alter content saliva Subjects condition would interfere conduct study Subjects currently use medication contraindicate use almotriptan Subjects currently use antiinflammatory medication History drug alcohol abuse would interfere study Subjects receive investigational drug use investigational device within 30 day enrollment previously participate CAPSS321 Employees investigator , study center , sponsor direct involvement study well family member employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>migraine</keyword>
	<keyword>biological marker</keyword>
	<keyword>rhinosinusitis</keyword>
	<keyword>CGRP</keyword>
	<keyword>histamine</keyword>
	<keyword>VIP</keyword>
</DOC>